secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2025-08-25T23:59:59+00:00
Accession:  0001193125-25-186994
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind to acquire scPharmaceuticals for $5.35/share plus CVR up to $1.00/share
--------------------------------------------------------------------------------

- Offer price: $5.35 cash + one contingent value right (CVR) per share; CVR milestones up to $1.00 aggregate.
- CVR milestones: FDA approval of SCP-111 injection by June 30, 2027 (Milestone 1) and $110M+ net sales of specified products by Dec 31, 2026 (Milestone 2).
- Principal stockholders holding ~11.5% of SCPH shares have agreed to tender and support the deal.
- MannKind obtained $175M incremental delayed draw term loan from Blackstone to finance transaction costs; will repay ~$81M of SCPH's Perceptive debt upon close.
- Strategic rationale: acquisition of FUROSCIX (approved for heart failure and chronic kidney disease) to expand into cardiorenal medicine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000119312525186994/0001193125-25-186994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000119312525186994/d931701d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-186994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer